ArticleClinical & translational immunology2024

A phase II study to evaluate the safety and efficacy of anlotinib combined with toripalimab for advanced biliary tract cancer.

Mingzhen Zhou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.